Study conducted at a site accredited by the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP), assuring data quality, reliability and consistency WAYNE, Pa., Aug.
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Hepatic artery infusion chemotherapy (HAIC) plus sintilimab and bevacizumab biosimilar (IBI305) in initial unresectable hepatocellular carcinoma (HCC): A retrospective study. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback